Clinical Trial

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Name: ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab — clinical trial record (NCT07320326)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASPIRE

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.

Trial Details

NCT Number	NCT07320326
Lead Sponsor	Peking University People's Hospital Collaborators: Pfizer
Conditions	TCE-RRMM
Enrollment	159 participants
Start Date	2025-12-30
Primary Completion	2028-07-18 (estimated)
Study Completion	2028-09-18 (estimated)
Updated on ClinicalTrials.gov	2026-01-06